Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus pentosus (recently reclassified as Lactiplantibacillus pentosus) is a species of probiotic lactic acid bacteria. [1] It is administered orally and is being investigated for its potential to modulate the gut microbiome and host immune system. [1, 8] A clinical study in children with atopic dermatitis (AD) investigated its effects on disease severity. [6, 11] While the study did not show a significant benefit over placebo for the overall group, it did note an improvement in subjective symptoms for a subgroup of children with allergen-sensitized AD. [6, 11] Its proposed mechanism involves restoring immune balance, producing antimicrobial substances, and enhancing the intestinal barrier function. [1, 7, 8] It is also studied for other conditions like gastrointestinal disorders, and for its antimicrobial properties in food preservation. [1, 5, 9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus pentosus.